Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468
Alexander Treiber, Ruben de Kanter, Catherine Roch, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 3, pp. 489-503
Open Access | Times Cited: 69

Showing 26-50 of 69 citing articles:

Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration
Clemens Muehlan, Margaux Boehler, Sander Brooks, et al.
Journal of Psychopharmacology (2019) Vol. 34, Iss. 3, pp. 326-335
Closed Access | Times Cited: 29
Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis.
Mathieu Rappas, A. Ali, K.A. Bennett, et al.
Journal of Medicinal Chemistry (2019) Vol. 63, Iss. 4, pp. 1528-1543
Closed Access | Times Cited: 26
Daridorexant for the Treatment of Insomnia
Christopher L. Robinson, Rajesh Supra, Evan Downs, et al.
Health psychology research (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 15
Daridorexant in Insomnia Disorder: A Profile of Its Use
Tina Nie, Hannah A. Blair
CNS Drugs (2023) Vol. 37, Iss. 3, pp. 267-274
Open Access | Times Cited: 8
Synthesis of Structurally Diverse N‐Substituted Quaternary‐Carbon‐Containing Small Molecules from α,α‐Disubstituted Propargyl Amino Esters
Natalia Mateu, Sarah L. Kidd, Leen Kalash, et al.
Chemistry - A European Journal (2018) Vol. 24, Iss. 51, pp. 13681-13687
Open Access | Times Cited: 26
Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies
Marie‐Laure Boof, Abir Alatrach, Mike Ufer, et al.
European Journal of Clinical Pharmacology (2018) Vol. 75, Iss. 2, pp. 195-205
Closed Access | Times Cited: 25
Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry
Clemens Muehlan, Hartmut Fischer, Dieter Zimmer, et al.
Current Drug Metabolism (2019) Vol. 20, Iss. 4, pp. 254-265
Closed Access | Times Cited: 23
Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study
Makoto Uchiyama, Daiji Kambe, Yumiko Imadera, et al.
Psychopharmacology (2022) Vol. 239, Iss. 7, pp. 2143-2154
Open Access | Times Cited: 13
Comparative efficacy of hypnotics in young and middle-aged adults with insomnia: a systematic review and network meta-analysis
Faizul Hasan, Hsin‐Chien Lee, Pin‐Yuan Chen, et al.
Sleep And Breathing (2023) Vol. 27, Iss. 5, pp. 2021-2030
Closed Access | Times Cited: 7
Interaction modes of human orexin 2 receptor with selective and nonselective antagonists studied by NMR spectroscopy
Kayo Imamura, Ken‐ichi Akagi, Yohei Miyanoiri, et al.
Structure (2024) Vol. 32, Iss. 3, pp. 352-361.e5
Open Access | Times Cited: 2
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects
Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, et al.
Drugs in R&D (2024) Vol. 24, Iss. 1, pp. 97-108
Open Access | Times Cited: 2
Transfer of the Dual Orexin Receptor Antagonist Daridorexant into Breast Milk of Healthy Lactating Women
Priska Kaufmann, Clemens Muehlan, Marion Anliker‐Ort, et al.
The Journal of Clinical Pharmacology (2024) Vol. 64, Iss. 10, pp. 1278-1287
Open Access | Times Cited: 2
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist
Benjamin Berger, Jasper Dingemanse, Giancarlo Sabattini, et al.
Clinical Pharmacokinetics (2021) Vol. 60, Iss. 10, pp. 1349-1360
Closed Access | Times Cited: 17
Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis
Uta Schilling, Andrea Henrich, Clemens Muehlan, et al.
Clinical Drug Investigation (2021) Vol. 41, Iss. 8, pp. 711-721
Closed Access | Times Cited: 17
Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist
Martine Géhin, Jolanta Wierdak, Giancarlo Sabattini, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 2, pp. 810-819
Open Access | Times Cited: 16
Pharmacokinetics and Pharmacodynamics of the Dual Orexin Receptor Antagonist Daridorexant in Japanese and Caucasian Subjects
Clemens Muehlan, Rob Zuiker, Pierre Peeters, et al.
Journal of Clinical Psychopharmacology (2020) Vol. 40, Iss. 2, pp. 157-166
Closed Access | Times Cited: 17
Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia
Aya Futamura, Ryo Suzuki, Yunoshin Tamura, et al.
Bioorganic & Medicinal Chemistry (2020) Vol. 28, Iss. 13, pp. 115489-115489
Closed Access | Times Cited: 15
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects
Benjamin Berger, Sander Brooks, Rob Zuiker, et al.
CNS Drugs (2020) Vol. 34, Iss. 12, pp. 1253-1266
Closed Access | Times Cited: 15
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
Benjamin Berger, Clemens Muehlan, Gernot Klein, et al.
Clinical and Translational Science (2021) Vol. 14, Iss. 6, pp. 2132-2138
Open Access | Times Cited: 13
A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
Wojciech Ziemichód, Karolina Grabowska, Antonina Kurowska, et al.
Molecules (2022) Vol. 27, Iss. 18, pp. 6041-6041
Open Access | Times Cited: 9
Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
Dwaipayan Sarathi Chakraborty, Shouvik Choudhury, Sandeep Lahiry
Sleep Science (2023) Vol. 16, Iss. 02, pp. 256-264
Open Access | Times Cited: 5
Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats
Michel A. Steiner, Michael Toeroek-Schafroth, Maria Elena Giusepponi, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 12, pp. 1249-1260
Open Access | Times Cited: 5
The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin
Isabelle Zenklusen, Clemens Muehlan, Ivan Ulč, et al.
Clinical and Experimental Pharmacology and Physiology (2020) Vol. 47, Iss. 11, pp. 1843-1849
Closed Access | Times Cited: 13
Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects
Benjamin Berger, Rüdiger Kornberger, Jasper Dingemanse
European Neuropsychopharmacology (2021) Vol. 51, pp. 90-104
Closed Access | Times Cited: 12
Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
Andreas Krause, Dominik Lott, Janneke M. Brussee, et al.
CPT Pharmacometrics & Systems Pharmacology (2022) Vol. 12, Iss. 1, pp. 74-86
Open Access | Times Cited: 8

Scroll to top